Hydroxychloroquine ‘Cocktail’ Fails NYC Hospital Test
U.S. regulators have approved a new type of coronavirus test
that administration officials have promoted as a key to opening up the country,
just days after a much-hyped treatment proved useless in a study of 1,400
patients at a New York hospital.
The Food and Drug Administration on Saturday announced
emergency authorization for antigen tests developed by Quidel Corp. of San
Diego. The test can rapidly detect fragments of virus proteins in samples
collected from swabs swiped inside the nasal cavity, the FDA said in a
statement.
The antigen test is the third type of test to be authorized
by the FDA.
Hydroxychloroquine, a drug touted by President Donald Trump
as a possible treatment for COVID-19, failed to help patients at New
York-Presbyterian Hospital, based on a report released earlier this week.
Researchers studied nearly 1,400 patients and 60% of them
were given hydroxychloroquine within 48 hours of arriving in the emergency
room. They did not benefit from the drug.
The study in the New England Journal of Medicine shows more
controlled trials are needed.
Dr. Vladimir Zelenko talked about using a “cocktail” of
hydroxychloroquine, an antibiotic and zinc are given very early in the
progression of the disease.
If given by the time a patient is exhibiting severe symptoms
of coronavirus, it may be too late for the “cocktail” to be effective.
Currently, the only way to diagnose active COVID-19 is to
test a patient’s nasal swab for the genetic material of the virus. While
considered highly accurate, the tests can take hours and require expensive,
specialized equipment mainly found at commercial labs, hospitals or
universities.
A second type looks in the blood for antibodies, the
proteins produced by the body days or weeks after fighting an infection. Such
tests are helpful for researchers to understand how far a disease has spread
within a community, but they aren’t useful for diagnosing active infections.
Antigen tests can diagnose active infections by detecting
the earliest toxic traces of the virus rather than genetic code of the virus
itself.
The FDA said that it expects to authorize more antigen tests
in the future.
Quidel said Saturday that the test can provide an accurate,
automated result in 15 minutes. The FDA’s emergency authorization “allows us to
arm our health care workers and first responders with a frontline solution for
COVID-19 diagnosis, accelerating the time to diagnosis and potential
treatment,” Douglas Bryant, CEO of Quidel, said in a statement.
The company said it specializes in testing for diseases and
conditions including the flu and Lyme disease.
The U.S. has tried to ramp up testing using the genetic
method, but the country’s daily testing tally has been stuck in the 200,000 to
250,000-per-day range for several weeks, falling far short of the millions of
daily tests that most experts say are needed to reopen schools, businesses,
churches and other institutions of daily life.
That’s led White House adviser Dr. Deborah Birx and other
federal officials to call for a “breakthrough” in the antigen tests.
“There will never be the ability on a nucleic acid test to
do 300 million tests a day or to test everybody before they go to work or to
school, but there might be with the antigen test,” Birx told reporters last
month.
Recently, the National Institutes of Health announced $1.5
billion in research grants aimed at fast-tracking the development of rapid,
easy-to-use testing approaches — including antigen tests — by the fall.
Comments
Post a Comment